A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis (NCT07012395)
Phase 2 Platform Trial to Assess the Efficacy and Safety of Long-acting Antibodies as Single Agents and in Combinations for Moderately to Severely Active Ulcerative Colitis
🩺 Plain-English Summary (8th-Grade Level)
This is a Phase 2, multicenter, proof-of-concept platform study in adult participants with moderately to severely active ulcerative colitis (UC). The primary goal of the study is to assess the efficacy and safety of multiple interventions following intravenous (IV) induction and subcutaneous (SC) maintenance treatment.
Who can join: Review the eligibility criteria below.
Location: Site 024 — Canoga Park, California
Age range: 18 Years to 75 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (267 Sites)
Showing the first 25 of 267 sites.
- Site 024 — Canoga Park, California
- Site 023 — La Jolla, California
- Site 012 — Lancaster, California
- Site 033 — Colorado Springs, Colorado
- Site 007 — Kissimmee, Florida
- 029 — Miami, Florida
- Site 038 — Chicago, Illinois
- Site 006 — Kansas City, Kansas
- Site 030 — Louisville, Kentucky
- Site 035 — Marrero, Louisiana
- Site 011 — Glen Burnie, Maryland
- Site 003 — Boston, Massachusetts
- Site 028 — Rochester, Minnesota
- Site 037 — New York, New York
- 040 — Chapel Hill, North Carolina
- Site 041 — Durham, North Carolina
- Site 016 — Winston-Salem, North Carolina
- Site 025 — Providence, Rhode Island
- Site 017 — Kingsport, Tennessee
- Site 013 — Cedar Park, Texas
- Site 005 — Garland, Texas
- Site 002 — San Antonio, Texas
- Site 008 — Southlake, Texas
- Site 009 — Webster, Texas
- Site 004 — Seattle, Washington
📞 Contact the Study Coordinator
Phone: (650) 402-4238
Email: info@skyline-uc.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Ulcerative Colitis
- A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001) — Dothan, Alabama
- Pharmacokinetics of IFX and TNF Concentrations in Serum, Stool, and Colonic Mucosa in Acute Severe Ulcerative Colitis — San Diego, California
- A Study to Evaluate the Safety of Ozanimod Exposure During Pregnancy in Women With Ulcerative Colitis and Their Infants — Eden Prairie, Minnesota
- CP101 for the Treatment of Ulcerative Colitis — Boston, Massachusetts
- A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis — Los Angeles, California
- Angiographic Delivery of AD-MSC for Ulcerative Colitis — Rochester, Minnesota
Explore by condition: All Ulcerative Colitis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.